Shovon Ashraf, Ph.D., a partner in Goodwin's Technology and Life Sciences groups, develops and implements strategies for procuring sophisticated worldwide patent estates toward furthering the business goals of public and private companies of all sizes through early-to-late stages of product development.

Dr. Ashraf works primarily in the life sciences, and procures and manages worldwide patent estates for biotechnology, pharmaceutical, diagnostics and medical device companies, and research institutions and hospitals, particularly in the fields of immuno-oncology, immunotherapy, therapeutic antibodies and multi-specific binding proteins, cell therapy, gene therapy, vaccines, enzyme replacement therapy, synthetic oligonucleotide therapeutics (e.g., antisense oligonucleotides), probiotics, drug-delivery device, and biomolecule-based drug-delivery systems. He also evaluates competitive landscapes to assess patentability and freedom to operate positions; performs IP due diligence for investors; advises on license agreements and research and collaboration agreements; and develops patent filing and prosecution strategies for minimizing the loss of patent term due to regulatory approval delay during the development of candidate therapeutic drug products, and for precluding the market entry of generic and/or follow-on therapeutics.

Areas of Practice
Domaines D’Expertise





Dr. Ashraf’s representative experience includes patent counseling and IP due diligence relating to the following deals:

  • Dragonfly Therapeutics in its $475 million exclusive license agreement with Bristol-Myers Squibb for Dragonfly’s IL-12 investigational immunotherapy program
  • Dragonfly Therapeutics in its exclusive research and collaboration agreement with Bristol-Myers Squibb with an upfront payment of $55 million to develop Dragonfly’s novel immunotherapies for multiple sclerosis and neuro-inflammation targets
  • Dragonfly Therapeutics in its strategic collaboration agreement with Merck with the potential to earn Dragonfly up to $695 million in upfront and milestone payments to develop Dragonfly’s TriNKETTM technology platform for a number of solid-tumor programs
  • QurAlis Corporation in its $42 million Series A financing to develop new therapies for Amyotrophic Lateral Sclerosis (ALS)
  • Anthos Therapeutics in its exclusive license agreement with Novartis for the development and commercialization of an anti-Factor XI/XIa antibody
  • Fresenius Medical Care in its strategic global partnership with Humacyte supported by a $150 million equity investment
  • Allena Pharmaceuticals in its $75 million initial public offering
  • Juvenescence Ltd. in its 14.4 million share purchase of AgeX Therapeutics for $43.2 million
Professional Activities

Dr. Ashraf is a member of the Boston Bar Association.

Professional Experience

Prior to joining Goodwin in 2016, Dr. Ashraf was an associate in the Intellectual Property group at Mintz Levin PC (Boston), and, prior to joining Mintz Levin, Dr. Ashraf was a Technical Specialist at Sterne, Kessler, Goldstein, & Fox (Washington, D.C.).


Dr. Ashraf has been named as a Massachusetts Rising Star by Super Lawyers in each year of 2015-2020.

In The News









J.D., 2013
The George Washington University Law School
M.S., Epidemiology, 2006
Harvard School of Public Health
Ph.D., Cell Biology, 2001
University of Massachusetts Medical School



U.S. Patent and Trademark Office (USPTO)
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique